Pfizer is positioning itself for a potential rebound as demand for its earlier coronavirus products declines and the company approaches a major patent cliff tied to Eliquis. The company’s strategy increasingly hinges on expanding its weight-management pipeline, including a GLP-1–based candidate inherited from Metsera, as the obesity drug market accelerates toward large-scale adoption.
However, analysts note that Pfizer faces intense competition from established leaders in obesity medicine, including Eli Lilly and Novo Nordisk, both of which already have widely used therapies and deep follow-on development programs.
Key takeaways
- Pfizer’s focus is shifting toward weight management after coronavirus-era revenue headwinds and an upcoming Eliquis patent cliff.
- Metsera acquisition bolstered the pipeline with MET-097i, now in phase 3 trials.
- Catalyst: obesity drug development remains the main driver of investor interest, particularly around efficacy and dosing convenience.
- Key implication: leadership is not guaranteed as rivals such as Eli Lilly and Novo Nordisk push next-generation obesity mechanisms.
What’s driving Pfizer’s weight-loss push
Pfizer’s obesity ambitions gained momentum after it discontinued certain internally developed anti-obesity programs due to safety concerns. In November, the company acquired Metsera for $7 billion in cash, excluding possible additional milestone payments, bringing multiple weight-loss assets into Pfizer’s portfolio.
The centerpiece is MET-097i, a GLP-1–based investigational medicine that demonstrated strong efficacy in phase 2b studies. According to the report, patients treated with MET-097i achieved mean placebo-subtracted weight loss of up to 14.1% after 28 weeks, alongside favorable tolerability. The candidate also has the potential for monthly dosing, a feature investors may view as a strategic differentiator versus current weekly injection regimens used in the category.
MET-097i is now moving through phase 3 trials. Pfizer also retained additional weight-management candidates from Metsera, and it has not abandoned all internal R&D efforts. One example highlighted is PF-07976016, an oral weight-loss pill in phase 2 studies. Pfizer’s internal and partnered pipeline coverage aims to broaden its reach beyond injectables, at a time when oral options could widen the addressable patient population.
Why investors are watching the obesity market
Across the industry, obesity medicine has shifted from an emerging therapeutic area toward a large and fast-growing commercial category. The article notes that the market could exceed $100 billion in sales by the next decade, underscoring why investors are treating pipeline progress as a potential substitute for declining demand in older franchises.
For Pfizer, the timing is also critical. The company is “racing toward” an Eliquis patent cliff by the end of the decade, and it has been dealing with weaker performance in recent years as coronavirus product demand has dropped. In this context, obesity therapies are framed as a way to rejuvenate the portfolio and support longer-term revenue stability.
Competition looks formidable
Even with a promising pipeline, Pfizer will be entering a crowded field dominated by established obesity-drug manufacturers. The article points to Eli Lilly and Novo Nordisk as current leaders, noting that both companies have effective products and deep development pipelines.
In particular, the report highlights Eli Lilly’s retatrutide, describing it as a next-generation obesity medicine supported by phase 3 results that the article says rival weight loss outcomes typically seen in bariatric surgery. Retatrutide’s mechanism is described as a triple agonist, meaning it activates multiple hormone receptors simultaneously.
The report also notes that, as of now, no triple-agonist obesity medicine has received U.S. Food and Drug Administration approval, leaving open the possibility that the first approved therapy could reshuffle the competitive landscape. Novo Nordisk is portrayed as working on multiple triple agonists as well, including one with encouraging mid-stage data.
Outside the top two, the article cites Amgen’s MariTide, which it says is in phase 3 studies as a potential treatment for obesity and other conditions, with an emphasis on longer-acting dosing that could be administered monthly or less frequently.
Market implication for Pfizer
The article’s central conclusion is that it may be difficult for Pfizer to secure overall leadership in obesity drugs, given the strength of rivals’ product and pipeline positions. Still, it argues that Pfizer may not need to dominate the category to drive meaningful business improvement. Instead, the company’s goal appears to be capturing share and building a multi-asset obesity franchise, supported by differentiated characteristics such as potential monthly dosing for MET-097i and the addition of an oral candidate.
Beyond weight management, the article also emphasizes that Pfizer’s pipeline includes other therapeutic areas—particularly oncology—that could contribute progress over the next few years. It additionally notes that several existing products have continued to post sales growth and portrays the stock as supported by a dividend profile, though the piece does not tie any specific new earnings or guidance to that claim.
Investors will likely focus on the next clinical milestones for MET-097i as well as competitive readouts from Eli Lilly and Novo Nordisk, especially as next-generation obesity mechanisms aim to convert breakthrough trial performance into scalable, regulator-approved therapies. The next major catalysts to watch are phase 3 data updates, any additional trial outcomes that clarify dosing convenience and durability, and broader updates around Pfizer’s portfolio reshaping as the company heads toward the Eliquis patent cliff.
